Early experience with XXXX for the treatment of @entity323 in renal transplant recipients.

@entity1 @entity323 @entity7855 @entity177
BACKGROUND: @entity323 ( @entity323 ) is common in @entity1 with @entity177 , but is not always alleviated following kidney transplant. The objective of the present study was to assess the feasibility in renal transplant @entity1 of @entity7855 treatment, an agent with proven efficacy in the management of @entity323 . METHODS: This was a phase IV, open, multicentre, 3 month, dose-escalation study. All @entity1 meeting the inclusion criteria were prescribed a dose of 50 mg @entity7855 at the first visit. Thereafter the dose could be increased to 100 mg or reduced to 25 mg based on efficacy or tolerability. The primary efficacy parameter assessed the ability of @entity1 to achieve erections sufficient for intercourse and to maintain erections after penetration. Secondary endpoints assessed @entity1 satisfaction with @entity7855 and the effect of @entity7855 on their quality of life. @entity1 were carefully monitored throughout the study for adverse events, interactions with immunosuppressive therapy and effect on graft function. RESULTS: The study included 50 @entity1 in the intent-to-treat population. @entity7855 significantly improved @entity1 's erection ability and the frequency of their erection maintenance. Analysis of the secondary efficacy parameters revealed that 66% of @entity1 believed treatment had improved their erections. @entity1 reported improvements in their sexual life and partner relationships and a high level of satisfaction with treatment. There were no interactions between @entity7855 and the immunosuppressive drugs and there was no significant adverse effect of @entity7855 on graft function. CONCLUSIONS: @entity7855 is an effective and well-tolerated agent for the treatment of @entity323 in renal transplant recipients.
